Literature DB >> 10668103

Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.

S Shepheard1, L Edvinsson, M Cumberbatch, D Williamson, G Mason, J Webb, S Boyce, R Hill, R Hargreaves.   

Abstract

This study investigated whether the selective 5HT1F receptor agonist LY334370 has other possible antimigraine mechanisms in addition to the proposed inhibition of dural plasma extravasation. LY334370 (up to 10(-5) M) had no vasoconstrictor effects on human cerebral arteries in vitro. It had no effect (up to 10 mg kg-1, i.v.) on neurogenic vasodilation of dural blood vessels produced by electrical stimulation of the dura mater in anesthetized rats. Nor had it any effect (at 3 mg kg-1, i.v.) on the hyperalgesia produced by injection of carrageenan into the paw of conscious rats or on nociceptive reflex responses in the spinalized, decerebrate rabbit (up to 3 mg kg-1, i.v.), indicating that it has no general analgesic properties. However, it significantly inhibited activation of second-order neurons in the trigeminal nucleus caudalis produced by electrical stimulation of the dura mater in anesthetised rats at 3 mg kg-1, i.v. These results provide evidence to suggest that LY334370 has a central mechanism of action in blocking the transmission of nociceptive impulses within the trigeminal nucleus caudalis and that this may represent a mechanism through which it has its antimigraine effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10668103     DOI: 10.1046/j.1468-2982.1999.1910851.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  18 in total

Review 1.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 2.  The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.

Authors:  Uwe Reuter; Heike Israel; Lars Neeb
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

Review 3.  Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.

Authors:  Matilde Capi; Martina Curto; Luana Lionetto; Fernando de Andrés; Giovanna Gentile; Andrea Negro; Paolo Martelletti
Journal:  Ther Adv Neurol Disord       Date:  2016-06-03       Impact factor: 6.570

4.  The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.

Authors:  D J Williamson; R G Hill; S L Shepheard; R J Hargreaves
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 5.  Emerging drugs for migraine prophylaxis and treatment.

Authors:  Marcelo E Bigal; Abouch V Krymchantowski
Journal:  MedGenMed       Date:  2006-05-04

6.  Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

Authors:  Kristian Agmund Haanes; Lars Edvinsson
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

7.  Migraine: an overview.

Authors:  Salvatore Salomone; Filippo Caraci; Anna Capasso
Journal:  Open Neurol J       Date:  2009-10-01

Review 8.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 9.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 10.  Update on future headache treatments.

Authors:  Abraham J Nagy; Alan M Rapoport
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.